1974
DOI: 10.1002/ijc.2910130314
|View full text |Cite
|
Sign up to set email alerts
|

Synergism between host anti‐tumor immunity and combined modality therapy against murine breast cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
6
0

Year Published

1974
1974
2006
2006

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 18 publications
1
6
0
Order By: Relevance
“…Every animal utilized in these experiments developed a tumor spontaneously, therefore, possible artifacts associated with transplantation into an unnatural site are obviated.) Treatment was initiated in animals carrying large tumors (averaging 0.5 g) at a time when the immune response against the tumor is already well developed (Stolfi et al, 1974(Stolfi et al, , 1975 and (since these tumors do not regress) obviously unsuccessful. To amplify any immunological benefit ensuing from splenectomy, the number of target cells in the host was reduced by ancillary treatment with enucleative tumor surgery or with enucleative tumor surgery plus cytoreductive combination chemotherapy.…”
Section: Introductionmentioning
confidence: 99%
“…Every animal utilized in these experiments developed a tumor spontaneously, therefore, possible artifacts associated with transplantation into an unnatural site are obviated.) Treatment was initiated in animals carrying large tumors (averaging 0.5 g) at a time when the immune response against the tumor is already well developed (Stolfi et al, 1974(Stolfi et al, , 1975 and (since these tumors do not regress) obviously unsuccessful. To amplify any immunological benefit ensuing from splenectomy, the number of target cells in the host was reduced by ancillary treatment with enucleative tumor surgery or with enucleative tumor surgery plus cytoreductive combination chemotherapy.…”
Section: Introductionmentioning
confidence: 99%
“…Of pertinence to immunotherapy studies, synergism between host antitumor immunity, surgery, and combination chemotherapy has been demonstrated in the CDsF 1 tumor system [12,13,23]. Further, in this CD8F 1 animal model, the immunostimulant, zymosan, produces an augmentation of tumor cures when employed as an adjuvant to combination chemotherapy following surgical removal of the CD8F 1 murine breast cancer 114, 15].…”
mentioning
confidence: 98%
“…Murine mammary carcinomas are immunogenic in their autochthonous hosts as are human breast cancers 13,9,17,[23][24][25]. Of pertinence to immunotherapy studies, synergism between host antitumor immunity, surgery, and combination chemotherapy has been demonstrated in the CDsF 1 tumor system [12,13,23].…”
mentioning
confidence: 99%
“…It has been firmly established that additive or synergistic effects can be obtained in vivo against neoplastic cells by properly combining CGR and antitumor agents (Ferrer and Mihich, 1967;Mihich, 1969;Bonmassar et al, 1970;Moore and Williams, 1973;Stolfi et al, 1974;Yamamura et al, 1980;Riccardi et al, 1980a). However, no data are presently available providing information on the combined effects of NR and chemotherapy on the inhibition of tumor cell growth.…”
mentioning
confidence: 99%